Article

Structure activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction

Université de Rennes1, Laboratoire Sciences Chimiques de Rennes, CNRS UMR 6226, Avenue du Général Leclerc, 35042 Rennes Cedex, France.
European Journal of Medicinal Chemistry (Impact Factor: 3.43). 02/2012; 51:286-93. DOI: 10.1016/j.ejmech.2012.02.036
Source: PubMed

ABSTRACT This paper describes the synthesis of nine selected diaryl/heteroaryl-containing phenol and polyphenol derivatives which have been evaluated against Bax/Bcl-xL interaction in comparison with ABT-737. Using a BRET assay, six of these derivatives exhibit activity comparable to ABT-737 to disrupt Bax/Bcl-xL interaction. These preliminary results demonstrate that such polyphenol-derived molecules are attractive compounds regarding anticancer activity and that the phenol at position 3 is important regarding disruption of Bax/Bcl-xL interaction.

0 Followers
 · 
104 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: We describe the synthesis of a series of new molecules containing phenol and triazoles moieties, compounds which have been evaluated for their ability to inhibit Bax/Bcl-xL interactions in cancer cells, by using BRET assays, and to induce cell death. Several derivatives exhibit a very promising activity, being more potent than the reference compounds acylpyrogallol A and ABT-737. These preliminary results demonstrate that derivatives of this family can be attractive to develop new molecules with potent anticancer activity.
    Bioorganic & medicinal chemistry letters 02/2014; 24(7). DOI:10.1016/j.bmcl.2014.02.035 · 2.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Protein-protein interactions (PPIs) are operative at all levels of cellular organization and function. Peptide stapling and hydrogen-bond surrogates, among other approaches, were used to improve the metabolic stability and cell membrane permeability of peptides, which is an important step toward PPI targeting therapeutics. Oligomeric structures such as foldamers represent highly promising, metabolically stable secondary structure mimics, while the structural diversity and biological relevance of natural products will continue to be a rich source for PPI drug discovery. Virtual screening can offer a cost-effective alternative to high-throughput screening (HTS), while supramolecular approaches represent novel orthogonal entries for PPI modulation. Accordingly, depending on the general principle of these screening methods and the biophysical characteristics that the proteins of interest have to possess, a differentiation can be made between surface based and proximity based assays.
    Chemical Reviews 04/2014; 114(9). DOI:10.1021/cr400698c · 45.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antimitotic agents such as microtubule inhibitors (paclitaxel) are widely used in cancer therapy while new agents blocking mitosis onset are currently in development. All these agents impose a prolonged mitotic arrest in cancer cells that relies on sustained activation of the spindle assembly checkpoint and may lead to subsequent cell death by incompletely understood molecular events. We have investigated the role played by anti-apoptotic Bcl-2 family members in the fate of mitotically arrested mammary tumor cells treated with paclitaxel, or depleted in Cdc20, the activator of the anaphase promoting complex. Under these conditions, a weak and delayed mitotic cell death occurs that is caspase- and Bax/Bak-independent. Moreover, BH3 profiling assays indicate that viable cells during mitotic arrest are primed to die by apoptosis and that Bcl-xL is required to maintain mitochondrial integrity. Consistently, Bcl-xL depletion, or treatment with its inhibitor ABT-737 (but not with the specific Bcl-2 inhibitor ABT-199), during mitotic arrest converts cell response to antimitotics to efficient caspase and Bax-dependent apoptosis. Apoptotic priming under conditions of mitotic arrest relies, at least in part, on the phosphorylation on serine 62 of Bcl-xL, which modulates its interaction with Bax and its sensitivity to ABT-737. The phospho-mimetic S62D-Bcl-xL mutant is indeed less efficient than the corresponding phospho-deficient S62A-Bcl-xL mutant in sequestrating Bax and in protecting cancer cells from mitotic cell death or yeast cells from Bax-induced growth inhibition. Our results provide a rationale for combining Bcl-xL targeting to antimitotic agents to improve clinical efficacy of antimitotic strategy in cancer therapy.
    Cell Death & Disease 10/2014; 5(6):e1291. DOI:10.1038/cddis.2014.251 · 5.18 Impact Factor
Show more